{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:59:48Z","timestamp":1780822788037,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.neuropharm.2025.110726","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:08:45Z","timestamp":1760998125000},"page":"110726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ticagrelor as a dual RAS modulator and mitochondrial stabilizer: A multifaceted neurotherapeutic strategy in Huntington's disease"],"prefix":"10.1016","volume":"283","author":[{"given":"Ola E.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-3658","authenticated-orcid":false,"given":"Rabab H.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-5530","authenticated-orcid":false,"given":"Dalaal M.","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Abou El-ezz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany","family":"El-Brairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan S.","family":"El-Abhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110726_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400846","article-title":"Dual inhibition of canonical and noncanonical PAR\u20101 by SCH79797 mitigates neurodegeneration in 3\u2010NP\u2010induced Huntington's disease: an in vivo and in silico approach","volume":"358","author":"Abdel\u2010Latif","year":"2025","journal-title":"Arch. Pharmazie"},{"key":"10.1016\/j.neuropharm.2025.110726_bib2","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1002\/jex2.65","article-title":"Defective mitochondria\u2010lysosomal axis enhances the release of extracellular vesicles containing mitochondrial DNA and proteins in Huntington's disease","volume":"1","author":"Beatriz","year":"2022","journal-title":"Journal of Extracellular Biology"},{"key":"10.1016\/j.neuropharm.2025.110726_bib3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41386-022-01519-7","article-title":"Microglial P2Y12 mediates chronic stress-induced synapse loss in the prefrontal cortex and associated behavioral consequences","volume":"48","author":"Bollinger","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110726_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.bbrc.2015.08.090","article-title":"Regulation of mitochondrial morphology and cell cycle by microRNA-214 targeting Mitofusin2","volume":"465","author":"Bucha","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2025.110726_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102289","article-title":"Boosting mitochondrial health to counteract neurodegeneration","volume":"215","author":"Burtscher","year":"2022","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.neuropharm.2025.110726_bib6","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1210\/en.2016-1879","article-title":"Angiotensin II causes \u03b2-cell dysfunction through an ER stress-induced proinflammatory response","volume":"158","author":"Chan","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2025.110726_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-022-03842-5","article-title":"Angiotensin-(1\u20137) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-\u03baB and MAPK pathways","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.neuropharm.2025.110726_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1126\/science.1231031","article-title":"PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria","volume":"340","author":"Chen","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2025.110726_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fendo.2017.00108","article-title":"Angiotensins and Huntington's disease: a study on immortalized progenitor striatal cell lines","volume":"8","author":"De Mello","year":"2017","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib10","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.4103\/1673-5374.368301","article-title":"Renin-angiotensin system in the central nervous system: focus on Huntington's disease","volume":"18","author":"de Miranda","year":"2023","journal-title":"Neural Regeneration Research"},{"key":"10.1016\/j.neuropharm.2025.110726_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2023.102743","article-title":"The ER-mitochondria interface, where Ca2+ and cell death meet","volume":"112","author":"de Ridder","year":"2023","journal-title":"Cell Calcium"},{"key":"10.1016\/j.neuropharm.2025.110726_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122362","article-title":"Morin suppresses mTORc1\/IRE-1\u03b1\/JNK and IP3R-VDAC-1 pathways: crucial mechanisms in apoptosis and mitophagy inhibition in experimental Huntington's disease, supported by in silico molecular docking simulations","volume":"338","author":"El-Emam","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110726_bib14","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1007\/s10753-022-01707-z","article-title":"Angiotensin II triggers NLRP3 inflammasome activation by a Ca2+ signaling-dependent pathway in rat cardiac fibroblast Ang-II by a Ca2+-dependent mechanism triggers NLRP3 inflammasome in CF","volume":"45","author":"Espitia-Corredor","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.neuropharm.2025.110726_bib15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/jpm11121309","article-title":"Huntingtin ubiquitination mechanisms and novel possible therapies to decrease the toxic effects of mutated Huntingtin","volume":"11","author":"Fiorillo","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.neuropharm.2025.110726_bib16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fnins.2018.00342","article-title":"Mitochondrial quality control in neurodegenerative diseases: focus on Parkinson's disease and Huntington's disease","volume":"12","author":"Franco-Iborra","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110726_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106667","article-title":"Characterization of fission and fusion mitochondrial dynamics in HD fibroblasts according to patient's severity status","volume":"201","author":"Gharaba","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110726_bib18","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3390\/antiox12081593","article-title":"Mitochondrial dysfunction in repeat expansion diseases","volume":"12","author":"Gim\u00e9nez-Bejarano","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.neuropharm.2025.110726_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2016.08.013","article-title":"Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease","volume":"96","author":"Guitart","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110726_bib21","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1172\/JCI70911","article-title":"Inhibition of mitochondrial fragmentation diminishes Huntington's disease\u2013associated neurodegeneration","volume":"123","author":"Guo","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuropharm.2025.110726_bib22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11064-023-04083-8","article-title":"Azilsartan Attenuates 3-Nitropropinoic acid-induced neurotoxicity in rats: the role of I\u0138B\/NF-\u0138B and KEAP1\/Nrf2 signaling pathways","volume":"49","author":"Hamouda","year":"2024","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2025.110726_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuro.2014.10.004","article-title":"Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: mitochondrial dysfunction and neurodegeneration","volume":"45","author":"Hariharan","year":"2014","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2025.110726_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1133863","article-title":"Dimethyl fumarate abrogates striatal endoplasmic reticulum stress in experimentally induced late-stage Huntington's disease: focus on the IRE1\u03b1\/JNK and PERK\/CHOP trajectories","volume":"14","author":"Hassab","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib25","first-page":"403","article-title":"Lifestyle-related diseases and anti-aging ophthalmology: suppression of retinal and choroidal pathologies by inhibiting renin-angiotensin system and inflammation","volume":"113","author":"Ishida","year":"2009","journal-title":"Nippon. Ganka Gakkai Zasshi"},{"key":"10.1016\/j.neuropharm.2025.110726_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.podrm.2021.10.003","article-title":"Ticagrelor","volume":"47","author":"Kabil","year":"2022","journal-title":"Profiles Drug Subst. Excipients Relat. Methodol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib27","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.3390\/ijms23147686","article-title":"Renin-angiotensin system in Huntington' s disease: evidence from animal models and human patients","volume":"23","author":"Kangussu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110726_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fonc.2016.00238","article-title":"The association of VDAC with cell viability of PC12 model of Huntington's disease","volume":"6","author":"Karachitos","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s11481-020-09978-9","article-title":"Pretreatment of indobufen and aspirin and their combinations with clopidogrel or ticagrelor alleviates inflammasome mediated pyroptosis via inhibiting NF-\u03baB\/NLRP3 pathway in ischemic stroke","volume":"16","author":"Li","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2022.01.060","article-title":"Ticagrelor for prevention of stroke and cognitive impairment in patients with vascular high-risk factors: a meta-analysis of randomized controlled trials","volume":"353","author":"Li","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2025.1565270","article-title":"Angiotensin-(1-7) protective effects in neurocognitive disorders: molecular mechanisms to therapeutic implications","volume":"16","author":"Lucas","year":"2025","journal-title":"Front. Physiol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jcma.2016.08.006","article-title":"Ang-(1\u20137) inhibited mitochondrial fission in high-glucose-induced podocytes by upregulation of miR-30a and downregulation of Drp1 and p53","volume":"79","author":"Ma","year":"2016","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2025.110726_bib33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/ijms23020780","article-title":"Impact of ER stress and ER-mitochondrial crosstalk in Huntington's disease","volume":"23","author":"Maity","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110726_bib34","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004424","article-title":"ER stress and its functional link to mitochondria: role in cell survival and death","volume":"3","author":"Malhotra","year":"2011","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174793","article-title":"Repositioning of Ticagrelor: renoprotection mediated by modulating renin-angiotensin system, inflammation, autophagy and galectin-3","volume":"918","author":"Mansour","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109771","article-title":"Morin post-treatment surpassed calpeptin in ameliorating 3-NP-induced cortical neurotoxicity via modulation of glutamate\/calpain axis, Kidins220, and BDNF\/TrkB\/AKT\/CREB trajectory","volume":"116","author":"Mohamed","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110346","article-title":"Antiplatelet therapy as a novel approach in Parkinson's disease: repositioning Ticagrelor to alleviate rotenone-induced parkinsonism via modulation of ER stress, apoptosis, and autophagy","volume":"269","author":"Muneeb","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110726_bib38","first-page":"191","article-title":"Abnormal platelet aggregation response in Huntington's disease","volume":"232","author":"Muramatsu","year":"1982","journal-title":"Arch. Psychiatry Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110726_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.740966","article-title":"Inhibition of Brain GTP cyclohydrolase I attenuates 3-nitropropionic acid-induced striatal toxicity: involvement of Mas receptor\/PI3k\/Akt\/CREB\/BDNF axis","volume":"12","author":"Mustafa","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbrc.2016.07.122","article-title":"Mitochondrial Ca2+ handling in Huntington's and Alzheimer's diseases\u2013Role of ER-mitochondria crosstalk","volume":"483","author":"Naia","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2025.110726_bib41","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"109","author":"Nguyen","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuropharm.2025.110726_bib42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fphar.2018.00176","article-title":"Mitochondrial fission is required for angiotensin II-induced cardiomyocyte apoptosis mediated by a Sirt1-p53 signaling pathway","volume":"9","author":"Qi","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib43","article-title":"Modulation of mitochondrial dynamics by the angiotensin system in dopaminergic neurons and microglia","author":"Quijano","year":"2024","journal-title":"Aging and Disease"},{"key":"10.1016\/j.neuropharm.2025.110726_bib44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bcp.2018.01.047","article-title":"Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor\/PI3K\/Akt\/BDNF pathway and inhibition of angiotensin II type-1 receptor\/NF-\u03baB axis","volume":"151","author":"Rabie","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113681","article-title":"Correlation between angiotensin 1\u20137-mediated mas receptor expression with motor improvement, activated STAT3\/SOCS3 cascade, and suppressed HMGB-1\/RAGE\/NF-\u03baB signaling in 6-hydroxydopamine hemiparkinsonian rats","volume":"171","author":"Rabie","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib46","doi-asserted-by":"crossref","first-page":"F1145","DOI":"10.1152\/ajprenal.00476.2016","article-title":"The nephron (pro) renin receptor: function and significance","volume":"311","author":"Ramkumar","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbadis.2011.10.016","article-title":"Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease","volume":"1822","author":"Reddy","year":"2012","journal-title":"Biochimica et Biophysica Acta-Molecular Basis of Disease"},{"key":"10.1016\/j.neuropharm.2025.110726_bib48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and neuropathology of Huntington's disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2022.07.024","article-title":"Cerebral blood flow is associated with markers of neurodegeneration in Huntington's disease","volume":"102","author":"Rocha","year":"2022","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/j.neuropharm.2025.110726_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.594945","article-title":"Peripheral levels of renin-angiotensin system components are associated with cognitive performance in huntington's disease","volume":"14","author":"Rocha","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110726_bib51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JHD-199003","article-title":"Huntington's disease clinical trials corner: june 2019","volume":"8","author":"Rodrigues","year":"2019","journal-title":"J. Huntingt. Dis."},{"key":"10.1016\/j.neuropharm.2025.110726_bib52","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1113\/expphysiol.2008.041988","article-title":"Characterization of a functional (pro) renin receptor in rat brain neurons","volume":"93","author":"Shan","year":"2008","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092937","article-title":"Direct pro-inflammatory effects of prorenin on microglia","volume":"9","author":"Shi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110726_bib54","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/hmg\/ddr024","article-title":"Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage","volume":"20","author":"Shirendeb","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2025.110726_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115578","article-title":"Interplay between the renin angiotensin system and oxidative stress contributes to alcohol addiction by stimulating dopamine accumulation in the mesolimbic pathway","volume":"212","author":"Sun","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib56","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/NEN.0b013e3181fa0308","article-title":"Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death","volume":"69","author":"Valenzuela","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.327","article-title":"Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration","volume":"7","author":"Valenzuela","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2025.110726_bib58","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s13311-023-01435-8","article-title":"The renin angiotensin system as a therapeutic target in traumatic brain injury","volume":"20","author":"Villapol","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2025.110726_bib59","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s43094-024-00724-z","article-title":"The potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2\/Ang1-7\/MAS receptor axis in 3-nitropropionic acid-induced Huntington's disease in rats: shifting paradigms in Huntington's disease treatment","volume":"10","author":"Wanas","year":"2024","journal-title":"Future Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.neuropharm.2025.110726_bib61","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3389\/fphys.2019.00411","article-title":"Mitofusin 2 participates in mitophagy and mitochondrial fusion against angiotensin II-induced cardiomyocyte injury","volume":"10","author":"Xiong","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.neuropharm.2025.110726_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-12205-w","article-title":"Effects of ticagrelor in a mouse model of ischemic stroke","volume":"7","author":"Yamauchi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110726_bib63","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/cells14040276","article-title":"Mitochondrial dysfunction in neurodegenerative diseases","volume":"14","author":"Yang","year":"2025","journal-title":"Cells"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:24:16Z","timestamp":1780820656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":61,"alternative-id":["S0028390825004344"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110726","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor as a dual RAS modulator and mitochondrial stabilizer: A multifaceted neurotherapeutic strategy in Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110726"}}